Patents by Inventor Sushant Malhotra

Sushant Malhotra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8058425
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: November 15, 2011
    Assignee: Eli Lilly and Company
    Inventors: Thomas Albert Engler, Timothy Paul Burkholder, Joshua Ryan Clayton, Clive Gideon Diefenbacher, Kelly Wayne Furness, James Robert Henry, Yihong Li, Sushant Malhotra, Angela Lynn Marquart, Johnathan Alexander McLean, David Mendel, Jon Kevin Reel, Brian Raymond Berridge, Charles Edward Ruegg, John Morris Sullivan
  • Patent number: 8022065
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Grant
    Filed: December 12, 2008
    Date of Patent: September 20, 2011
    Assignee: Eli Lilly and Company
    Inventors: Thomas Albert Engler, James Robert Henry, Sushant Malhotra, Jon Kevin Reel
  • Publication number: 20110207721
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Application
    Filed: May 4, 2011
    Publication date: August 25, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Thomas Albert Engler, Timothy Paul Burkholder, Joshua Ryan Clayton, Clive Gideon Diefenbacher, Kelly Wayne Furness, James Robert Henry, Yihong Li, Sushant Malhotra, Angela Lynn Marquart, Johnathan Alexander McLean, David Mendel, Jon Kevin Reel, Brian Raymond Berridge, Charles Edward Ruegg, John Morris Sullivan
  • Publication number: 20090105229
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Application
    Filed: December 12, 2008
    Publication date: April 23, 2009
    Inventors: Thomas Albert Engler, Timothy Paul Burkholder, Joshua Ryan Clayton, Clive Gideon Diefenbacher, Kelly Wayne Furness, James Robert Henry, Yihong Li, Sushant Malhotra, Angela Lynn Marquart, Johnathan Alexander McLean, David Mendel, Jon Kevin Reel
  • Patent number: 7511056
    Abstract: The present invention is directed to inhibitors of TGF-? of Formula I:
    Type: Grant
    Filed: November 2, 2005
    Date of Patent: March 31, 2009
    Assignee: Eli Lilly and Company
    Inventors: Clive Gideon Diefenbacher, Thomas Albert Engler, Hong-Yu Li, Sushant Malhotra, Jason Scott Sawyer, Yan Wang
  • Publication number: 20080262004
    Abstract: The present invention is directed to inhibitors of TGF-? of Formula I:
    Type: Application
    Filed: November 2, 2005
    Publication date: October 23, 2008
    Applicant: ELI LILLY AND COMPANY
    Inventors: Clive Gideon Diefenbacher, Thomas Albert Engler, Hong-Yu Li, Sushant Malhotra, Jason Scott Sawyer, Yan Wang
  • Patent number: 7405305
    Abstract: The present invention provides kinase inhibitors of Formula (I)
    Type: Grant
    Filed: March 5, 2003
    Date of Patent: July 29, 2008
    Assignee: Eli Lilly and Company
    Inventors: Pamela Ann Albaugh, Jochen Ammenn, Timothy Paul Burkholder, Joshua Ryan Clayton, Scott Eugene Conner, Brian Eugene Cunningham, Thomas Albert Engler, Kelly Wayne Furness, James Robert Henry, Sushant Malhotra, Mark Joseph Tebbe, Guoxin Zhu, YiHong Li, Brian Raymond Berridge, Charles Edward Ruegg, John Morris Sullivan
  • Patent number: 7405299
    Abstract: The current invention relates to compounds of the formula: (Ia) and the pharmaceutically acceptable salts thereof and their use as TGF-beta signal transduction inhibitors for treating cancer and other diseases in a patient in need thereof by administration of said compounds.
    Type: Grant
    Filed: November 24, 2003
    Date of Patent: July 29, 2008
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Timothy Paul Burkholder, Todd Vincent Decollo, Alexander Glenn Godfrey, Charles Raymond Heap, Chi-Hsin Richard King, Hong-Yu Li, William Thomas McMillen, Jason Scott Sawyer, Yan Wang, Clive Gideon Diefenbacher, Thomas Albert Engler, Sushant Malhotra, Sreenivasa Reedy Mundla
  • Patent number: 7109229
    Abstract: The compounds disclosed herein are indolocarbazoles of Formula (I), which are potent CDK4 inhibitors, and are useful in the treatment of cell proliferative disorders, including cancer. Formula (I).
    Type: Grant
    Filed: September 24, 2001
    Date of Patent: September 19, 2006
    Assignee: Eli Lilly and Company
    Inventors: Thomas Albert Engler, Kelly Wayne Furness, Sushant Malhotra, Stephen Lyle Briggs, Harold Burns Brooks, David K yes Clawson, Concepcion Sanchez-Martinez, Faming Zhang, Guoxin Zhu
  • Publication number: 20060058295
    Abstract: The current invention relates to compounds of the formula: (Ia) and the pharmaceutically acceptable salts thereof and their use as TGF-beta signal transduction inhibitors for treating cancer and other diseases in a patient in need thereof by administration of said compounds.
    Type: Application
    Filed: November 24, 2003
    Publication date: March 16, 2006
    Applicant: Eli Lilly and Company
    Inventors: Douglas Beight, Timothy Burkholder, Todd Decollo, Alexander Godfrey, Charles Heap, Chi-Hsin King, Hong-Yu Li, William McMillen, Jason Sawyer, Yan Wang, Clive Diefenbacher, Thomas Engler, Sushant Malhotra, Sreenivasa Mundla
  • Publication number: 20050288321
    Abstract: The present invention provides kinase inhibitors of Formula (I).
    Type: Application
    Filed: March 5, 2003
    Publication date: December 29, 2005
    Inventors: Pamela Albaugh, Jochen Ammenn, Timothy Burkholder, Joshu Clayton, Scott Conner, Brian Cunningham, Thomas Engler, Kelly Furness, James Henry, Sushant Malhotra, Mark Joseph Tebbe
  • Publication number: 20050090483
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Application
    Filed: March 4, 2003
    Publication date: April 28, 2005
    Inventors: Thomas Engler, Timothy Burkholder, Joshua Clayton, Clive Diefenbacher, Kelly Furness, James Henry, Yihong Li, Sushant Malhotra, Angela Marquart, Johnathan McLean, David Mendel, Jon Reel
  • Publication number: 20040048915
    Abstract: The compounds disclosed herein are indolocarbazoles of Formula (I), which are potent CDK4 inhibitors, and are useful in the treatment of cell proliferative disorders, including cancer. Formula (I).
    Type: Application
    Filed: February 7, 2003
    Publication date: March 11, 2004
    Inventors: Thomas Albert Engler, Kelly Wayne Furness, Sushant Malhotra, Stephen Lyle Briggs, Harold Burns Brooks, David Keyes Clawson, Concepcion Sanchez-Martinez, Faming Zhang, Guoxin Zhu